Detalhe da pesquisa
1.
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Eur J Haematol
; 108(1): 73-83, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34496096
2.
Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point.
Haematologica
; 100(8): e328-30, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25840600
3.
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Leuk Lymphoma
; 61(8): 1850-1859, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32268815